Beach Crasher and Cataract Kush: the same THC range, two different leading terpenes

How do these two strains really differ?

By the leading terpene and lineage, not potency. Databases report the same THC content range for both cultivars and the same trio of producers, so the number on the label does not distinguish them at all. What separates them is the composition: Beach Crasher is led by caryophyllene, while Cataract Kush is led by myrcene.

The range of 16.2-24.2% appears in this comparison fifteen times out of eighty-five cultivars, so it does not stand out on its own. It was created by combining several separate registry entries with two levels of declared potency, one for each producer and level. The pharmacy issues such a single entry, not a strain understood as a name, and its packaging carries the declared value.

The second difference lies in the genetic description and is visible at first glance. All pharmaceutical entries describe Cataract Kush the same way, as an indica strain. Beach Crasher has two descriptions at once: one database calls it a hybrid, the other a hybrid with indica dominance. Such a discrepancy is not a transcription error, but a trace that the genetic label comes from a catalog description, not from a measurement taken on a batch.

What connects them?

The same trio of producers, the same potency range, and six common terpenes. The entire profile of Cataract Kush fits within the profile of Beach Crasher: no terpene listed for one strain is absent from the other, and Beach Crasher adds two more entries to this set.

On the lineage side, there is also a common point, but it requires caution. Cataract Kush comes from the crossing of LA Confidential with OG Kush, and that is how the breeder records it. The second parent of Beach Crasher is TK Bx1, which is the first backcross of the Triangle Kush line. Some studies describe Triangle Kush as a Florida phenotype of OG Kush, while the seed bank traces it back to random pollination of Emerald Triangle plants with Hindu Kush pollen. Therefore, the common ancestor is a hypothesis in the industry, not a record from the card.

OG Kush behaves in this comparison like a family name, not like a single plant: four cultivars have it directly listed as a parent, while two others have its branch. Therefore, the kinship field is empty for both strains, and this is a correct result, not a gap to be filled. The name component proves even less: the word kush carries ten names here, and for five of them, the lineage remains undetermined.

Which of the two terpene profiles is better documented?

Neither is well documented, but they differ in the type of absence. The Beach Crasher profile is described by two sources, and these sources differ in composition: bisabolol, limonene, and linalool are mentioned by only one of them. The Cataract Kush profile is described by one source, so there is nothing to compare it to.

The discrepancy does not end with the list of names. The same database provides two different sets for Beach Crasher depending on the registration position, and the shares expressed in percentages sum up to 86 in one of them and to exactly one hundred in the other, while for Cataract Kush it sums to 94. Since sometimes the total reaches one hundred and sometimes it does not, the denominator is unknown and different for each position. Hence the decision to present the composition as a list, without a number next to the name.

The practical effect is that the comparison of the profiles of these two strains compares two catalog descriptions, not two analyses. For Beach Crasher, the choice of source even changes what accompanies the leading terpene: one entry lists nerolidol in the description, while another does not mention it at all. For Cataract Kush, there is no choice, as there is only one description, and the absence of contradictions is not the same as confirmation.

What has been shown for caryophyllene, the leading terpene of Beach Crasher?

Two studies on mice, both about pain and inflammation, neither about the strain itself. The first showed that caryophyllene binds to the CB2 receptor and that without this receptor its anti-inflammatory effect disappears. The second described the analgesic effect after oral administration in rodents.

Gertsch and colleagues described this first in 2008 (PMID:18574142): the binding was selective, and the paw swelling subsided in normal mice but not in those lacking the CB2 receptor. The model included a mouse and the binding assay in vitro on human cells, so it speaks about the mechanism, not about a patient. Klauke and colleagues in 2014 (PMID:24210682) worked on a mouse model and described a reduction in the late inflammatory phase of pain after oral administration, with chronic administration not leading to tolerance.

Both of these studies share a common boundary. In neither of the two studies was caryophyllene tested on humans or in inhaled form from dried flower; both studies concern oral or systemic administration in mouse models of pain and inflammation, not sleep or mood.

It is worth comparing this record with what the sales card says about the strain. For both Beach Crasher and Cataract Kush, the same database lists one word in the possible effects column: relaxing. This is a catalog label and user feedback, not a measurement result, and it does not differentiate these two entries in any way.

What has been shown for myrcene, the leading terpene of Cataract Kush?

Three studies on mice, and their results do not form a single answer. Administration into the peritoneal cavity prolonged sleep induced by pentobarbital, but it performed poorly in the anxiety test. Inhalation administration provided an anxiolytic effect only in females. The third study concerned pain and indicated a mechanism outside the cannabinoid system.

The Vale team described in 2002 (PMID:12587690) a decrease in the locomotor activity of mice and more than a twofold increase in sleep at the higher of the tested doses, along with fewer entries into the open arms of the maze, which the authors called a weak anxiogenic effect. The Rao team in 1990 (PMID:1983154), also on mice, described a reduction in pain responses, reversed by naloxone and yohimbine. The Wagner team in 2024 (PMID:39728677) administered puffs in short inhalations, mimicking inhalation, and achieved an anxiolytic effect in females, while in males, it occurred only with a single puff.

These three studies have a boundary recorded more broadly. In humans, it has not been shown that myrcene alleviates insomnia at doses typical for inhalation of dried flower. The direction of the effect in rodents depends on the route of administration and sex: after intraperitoneal injection in 2002, a slightly anxiogenic effect was described, while after inhalation in 2024, an anxiolytic effect was noted in females. These two results do not negate each other; they only show that the conclusion depends on conditions that no popular strain database provides.

For the comparison of two strains, this has one consequence. Results with opposite signs come from different routes of administration and from animals of different sexes, and the name of the cultivar does not carry any of these conditions. Cataract Kush is listed in the catalog as an indica-type strain with a relaxing effect column, but this is based on the seller's description, not any of the three cited studies.

How long does the effect last for each of these two strains?

Equally long, because the course is determined by the route of administration, not the strain name. Neither for Beach Crasher nor for Cataract Kush has anyone measured the duration of effects separately, so any difference provided in commercial descriptions is user feedback, not a measurement.

The route of administration determines the course more than the variety itself. After vaporization, the substance passes from the lungs to the blood almost immediately, so the first sensations appear after a few minutes, the intensity increases for another ten to thirty minutes, and the whole effect lasts for two to four hours. After ingestion, the raw material first passes through the intestine and liver, so the first sensations are awaited from half an hour to two hours, and the episode can last six, sometimes eight hours. Hence the most common mistake with oral administration: anyone who thinks nothing is happening after thirty minutes and takes another dose will receive both doses at once. The above ranges describe the route of administration, not this variety; pharmacokinetic studies for a single cultivar have not been published.

This leads to a simple conclusion that organizes the entire comparison. Since the course depends on the route of administration, two strains administered the same way differ at most in what the profile carries, and neither of their profiles has been confirmed by a series analysis. Therefore, the question of which lasts longer does not have an answer based on data.

What side effects have been reported for each of these two strains?

Separately, nothing has been reported for either of them. Reports go to the registry under the product's batch number, not under the cultivar name, so the difference in the number of descriptions for Beach Crasher and Cataract Kush would speak of the popularity of the item, not its safety.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

Both strains share the same trio of producers, so even if reports could be broken down by names, the difference between them would blend with the difference between batches. The only honest statement is that both items are subject to the same description of the raw material group, and discussions about symptoms should be held with the treating physician, not with the strain description.

Why does the availability of both strains change over time?

Because there is no strain in the pharmacy, there is a registration position of a specific producer. Each of these two names stands under four such positions, and at the time of collecting data for this comparison, two of them were listed as unavailable, so the picture changes without a change in name.

The distribution is asymmetrical in a way that is not visible by name. For Beach Crasher, the available positions were S-LAB and Tilray, while the expired positions were S-LAB and Synoptis Pharma, meaning the same producer stood on both sides. For Cataract Kush, the available positions were S-LAB and Tilray, while the expired positions were Synoptis Pharma and Tilray. The current state of releases is kept separately updated. by a comparison of strains available in pharmacies, because the catalog ages faster than the text.

Finally, a note on naming, as two different shelves can be confused. The store dried flower category on ubucha.pl is a different shelf than a pharmacy: it features dried flower of industrial hemp with cannabidiol, sold over the counter, without a common entry with the raw material described above. Full profiles of both cultivars are detailed separately on the strain page Beach Crasher oraz na stronie odmiany Cataract Kush.

Frequently Asked Questions

Are Beach Crasher and Cataract Kush the same strain family?

Not in the sense that the breeder's card understands family. Cataract Kush has OG Kush listed directly as a parent, while Beach Crasher's lineage is traced through a second parent, TK Bx1. However, OG Kush in this context refers to a broad family name, not a single plant, so a common ancestor does not make these two strains siblings.

Which of these two strains is stronger?

Neither, if the question concerns the numbers on the label. Both have the same range of 16.2-24.2% in the registry, as they are listed under several separate registry entries with two levels of declared strength. The specific packaged entry carries its own value, not the strain name.

Why are there no percentage shares of terpenes in this text?

Because the denominator of these shares is unknown. In the same database, the shares given for one entry of Beach Crasher sum to 86, for another entry of the same strain to exactly one hundred, and for Cataract Kush to 94. A number without a denominator appears in a text about anxiety as a measurement, but it is not, so the composition is presented here as a list of names.

Does myrcene help with sleep?

This has not been demonstrated in humans. A study from 2002 extended sleep induced by pentobarbital in mice, but after injection into the peritoneal cavity and at doses incomparable to inhalation of dried flower. A study from 2024 administered it via inhalation and measured anxiety, not sleep, and the result depended on the sex of the animals.

Does caryophyllene have analgesic effects in humans?

There is no data from studies in humans. Both studies referenced in this text were conducted on mice, with oral or systemic administration, not inhalation, and concerned inflammatory and neuropathic pain in animal models.

Where do the differences in descriptions of the same strain come from?

From the fact that the description comes from a catalog, not from the analysis of a single batch. For Beach Crasher, two databases provide different sets of terpenes, and even one database describes two registry entries of the same cultivar differently. For Cataract Kush, there is one description, so there are no contradictions, which does not mean that the composition has been confirmed.

The material is for informational purposes. Dried flower is a pharmaceutical raw material dispensed by a doctor's prescription in the Rpw category, and the method of treatment is determined by the attending physician. The editorial text was prepared by redakcja ubucha.pl.